Development Pipeline
Every program below is pre-clinical. Two oral small molecules for cardiometabolic disease, an oral small-molecule series for MASH, and a peripherally restricted analgesic. Target and composition details are not disclosed.
XI-D
Oral small molecule
Obesity, type 2 diabetes and related cardiometabolic disease
Oral, non-peptidic small molecule designed from a single scaffold and benchmarked against the approved oral reference standard.
XI-T
Oral small molecule
Obesity, type 2 diabetes and related cardiometabolic disease
Oral small molecule extending the earlier profile with an additional designed activity and a built-in selectivity gate.
XI-MTR
Oral small molecule
MASH with fibrosis (F2–F3); type 2 diabetes and insulin resistance; dyslipidemia
Oral small-molecule series in computational design. Predicted properties only; no in vitro or in vivo data yet.
PNX-M11
Peripherally restricted analgesic
Acute and chronic pain
A single molecule combining complementary peripheral mechanisms, with CNS exclusion designed into the physicochemistry rather than added afterwards.
Stages progress from XI (AI), our internal computational stage, through Discovery and clinical development. Programs move on this page only when the underlying work is complete.
